Compare SEM & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEM | MNKD |
|---|---|---|
| Founded | 1996 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.8B |
| IPO Year | 2009 | 2004 |
| Metric | SEM | MNKD |
|---|---|---|
| Price | $16.38 | $5.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $16.33 | $10.08 |
| AVG Volume (30 Days) | 708.7K | ★ 3.8M |
| Earning Date | 02-19-2026 | 02-23-2026 |
| Dividend Yield | ★ 1.53% | N/A |
| EPS Growth | N/A | ★ 23.47 |
| EPS | ★ 0.87 | 0.10 |
| Revenue | ★ $5,368,760,000.00 | $313,787,000.00 |
| Revenue This Year | $5.53 | $21.29 |
| Revenue Next Year | $4.33 | $25.53 |
| P/E Ratio | ★ $21.56 | $57.82 |
| Revenue Growth | ★ 45.29 | 17.43 |
| 52 Week Low | $11.65 | $3.38 |
| 52 Week High | $19.54 | $6.51 |
| Indicator | SEM | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 76.45 | 48.15 |
| Support Level | $14.96 | $5.54 |
| Resistance Level | $15.73 | $6.05 |
| Average True Range (ATR) | 0.31 | 0.29 |
| MACD | 0.12 | -0.01 |
| Stochastic Oscillator | 92.11 | 28.24 |
Select Medical Holdings Corp is a healthcare company that operates through three segments: critical illness recovery hospitals, rehabilitation hospitals, and outpatient rehabilitation clinics. Critical illness recovery hospitals which derives maximum revenue consists of hospitals designed to serve the needs of patients recovering from critical illnesses, often with complex medical needs. The rehabilitation hospital segment consists of hospitals designed to serve patients that require intensive physical rehabilitation care. Patients are typically admitted to critical illness recovery hospitals and rehabilitation hospitals from general acute care hospitals. The outpatient rehabilitation segment consists of clinics that provide physical, occupational, and speech rehabilitation services.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.